Early results from a multicenter trial on SGLT2 inhibitors in heart failure with preserved ejection fraction
The trial reports a reduction in the composite primary outcome. Here's what was measured, who was included, and the limits to keep in mind before changing practice.
[Demo] SGLT2 inhibition in heart failure with preserved ejection fraction: a multicenter trialDemo Journal of Cardiology · 2026doi:10.5555/demo.hfpef.2026
Do SGLT2 inhibitors improve outcomes in heart failure with preserved ejection fraction?Human expert review completed2 reviews
Rigor
Expert-reviewed
Qualified reviewers assessed the methods and statistics. This does not mean the result is settled. Reach (likes, shares) never changes this label.